Member of Lyonbiopole
Founded in 2015 by two scientists, Géraldine Le Duc (CEO of NH TherAguix) and Pr Olivier Tillement (Professor of Chemistry at University of Lyon), NH TherAguix is a French biotechnology company based in Grenoble. NH TherAguix has developed an innovative theranostic nanodrug called AGuIX® that allows to fight more efficiently against all forms of cancer.
Thanks to a €13M fund raising in 2019 (BPI, Innobio, Omnes, Arbevel, Supernova), NH THerAguix was able to launch a promising portfolio of clinical trials.
Strategic application domain: Human Medicine
Application market: Oncology
Type of activity: Diagnostics, Therapeutics, Pharma or Biotech
Technologies: Drug delivery device & Technologies, Imaging, Nanotechnology
Created on dec. 15th, 2015 - 12 employees
Address
29 chemin du vieux chêne 38240 Meylan
Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.